New Wonder Drug Shows Advanced Advantages in Cushing’s Care

Long-term treatment shown to lower blood pressure, sugar in patients

Isturisa (osilodrostat) use long term may help lower blood pressure and blood sugar levels in people living with Cushing’s disease who have high blood pressure. Use of this medication for up to 1.4 years has helped to ease hypertension and control diabetes in Cushing’s disease.

Patients involved in two global Phase 3 clinical trials, the analysis found;

“[Co-occurring] hypertension and diabetes improved in many patients with Cushing’s disease during long-term [Isturisa] therapy, with many patients able to stop/reduce the dose of antihypertensive or antihyperglycemic medications,” the researchers wrote.

The data indicate that Isturisa “effectively controls [high cortisol levels], leading to improved clinical signs, and may reduce treatment burden associated with [co-occurring conditions] in patients with Cushing’s disease,” the team wrote.

The study shows “Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies,” was published in the journal Pituitary. The work was funded by Novartis, Isturisa’s original developer, and by Recordati, which now markets the therapy.

In Cushing’s disease, a tumor in the brain’s pituitary gland leads to the excessive production of adrenocorticotropic hormone, known as ACTH, which in turn stimulates the adrenal glands atop the kidneys to produce excessively high levels of the hormone cortisol. Elevated cortisol levels drive Cushing’s disease symptoms and other health problems. Such problems, which often include high blood pressure and blood sugar dysregulation, can set the stage for diabetes and hypertension.

Isturisa is an has been approved in the U.S. and Japan, and in the European Union, to treat Cushing’s disease in patients for whom surgery to remove the disease-driving tumor is not an option or is not effective. It works by inhibiting an enzyme involved in cortisol production.

To read more, open the link below :